Davita Inc Stock Price, News & Analysis

DaVita Inc. (NYSE: DVA) has successfully upsized and priced its private offering of 6.750% senior notes due 2033 from $750 million to $1 billion. The notes were priced at 100.000% of their face value, yielding a 6.750% coupon. The offering is expected to close on May 23, 2025.

The company plans to use the proceeds to repay outstanding revolving credit facility borrowings, cover related costs and fees, and if funds remain, for general corporate purposes including stock repurchases, working capital, and capital expenditures. The notes were offered exclusively to qualified institutional buyers under Rule 144A and certain non-U.S. persons under Regulation S of the Securities Act.

DaVita (NYSE: DVA) has released its 2024 Community Care report, marking significant achievements in its ESG initiatives. Key highlights include: a record 8,200+ kidney transplants, 15% of patients utilizing home dialysis, and over 40,000 participants in Kidney Smart® education programs. The company demonstrated strong teammate engagement with 84% reporting workplace belonging and 147,000+ volunteerism hours. In environmental stewardship, DaVita is on track for 100% renewable energy matching by 2025 and saved 75+ million gallons of water in 2024. The company expanded community health initiatives through its Health Tour and provided 100,000+ medically tailored meals through the Food is Medicine Coalition. Corporate governance remained strong with 90% independent board members and 99.9% compliance training completion.

DaVita Inc. (NYSE: DVA) has announced a private offering of $750 million senior notes due 2033. The company plans to use the proceeds to repay outstanding revolving credit facility borrowings and related interest, cover associated costs and fees, and if funds remain, for general corporate purposes including stock repurchases, working capital, and capital expenditures.

The notes are being offered exclusively to qualified institutional buyers under Rule 144A of the Securities Act and certain non-U.S. persons under Regulation S. The offering is not registered under the Securities Act or other jurisdictions' securities laws and cannot be sold in the United States without registration or an applicable exemption.

DaVita Inc. (DVA) reported its Q1 2025 financial results with consolidated revenues of $3.224 billion and operating income of $439 million. The company achieved diluted earnings per share of $2.00, down from $2.65 in Q1 2024. Operating cash flow was $180 million, while free cash flow was $(45) million. DaVita repurchased 3.7 million shares at an average price of $148.94 per share. The company served approximately 282,000 patients across 3,173 outpatient dialysis centers, with 2,661 centers in the U.S. and 512 internationally. Revenue per treatment increased to $400.14, up from $384.54 year-over-year. For 2025, DaVita projects adjusted operating income between $2,010-$2,160 million and adjusted diluted EPS of $10.20-$11.30.

DaVita has announced its upcoming first quarter 2025 investor conference call, scheduled for Monday, May 12, 2025, at 5:00 p.m. Eastern Time. The company will release its Q1 results after the market closes on the same day.

Investors can participate through multiple channels:

• Webcast: Available via DaVita IR web page
• Domestic dial-in: 877-918-6630
• International dial-in: 517-308-9042

Participants must provide the password "Earnings" along with their name and company affiliation when calling in. While a replay will be accessible through the company's investor website (investors.davita.com), no telephone replay option will be available.

DaVita Inc. (NYSE: DVA) has announced its participation in the upcoming Barclays Global Healthcare Conference 2025. The company's CFO Joel Ackerman and Group VP of Investor Relations Nic Eliason will engage in a fireside chat with investors on March 11, 2025, at 9:00 a.m. EDT.

DaVita is a comprehensive kidney care provider with a 25-year track record in clinical quality and innovation. As of December 31, 2024, the company serves 281,100 patients across 3,166 outpatient dialysis centers, with 2,657 centers in the United States and 509 centers across 13 other countries. The company specializes in various aspects of kidney health, from disease progression management to transplantation support and home dialysis services.

DaVita Inc. (NYSE: DVA) reported strong financial results for Q4 2024. Consolidated revenues reached $3.295 billion for Q4 and $12.816 billion for the full year. The company achieved operating income of $565 million and adjusted operating income of $491 million in Q4, with full-year figures of $2.090 billion and $1.981 billion respectively.

Q4 diluted earnings per share was $3.09, with adjusted EPS at $2.24. Operating cash flow stood at $548 million with free cash flow of $281 million for the quarter. The company actively engaged in share repurchases, buying back 2.3 million shares at an average price of $156.46 per share in Q4.

DaVita provided dialysis services to approximately 281,100 patients across 3,166 outpatient centers globally, with 2,657 centers in the US and 509 centers across 13 other countries. However, U.S. dialysis treatments showed a per-day decrease of 1.4% compared to Q3 2024.

DaVita Inc. (NYSE: DVA) has announced its upcoming fourth quarter 2024 investor conference call, scheduled for Thursday, February 13, 2025, at 5:00 p.m. Eastern Time. The company will release its financial results after the market closes on the same day.

The conference call will be accessible via webcast through DaVita's IR web page. Participants can join through the provided webcast link or by calling 877-918-6630 (domestic) or 517-308-9042 (international). Callers must provide the password 'Earnings' along with their name and company affiliation.

While a webcast replay will be available on investors.davita.com for those unable to attend the live call, there will be no telephone replay option available.

DaVita marks its 25th anniversary of kidney care excellence, highlighting significant achievements in healthcare innovation and patient care since 2000. The company reports notable progress in 2024, including a record-breaking 8,200 patient kidney transplants and 15% of patients receiving home dialysis treatment.

Key accomplishments include rapid disaster response during Hurricanes Helene and Milton, expanding global operations to 14 countries including new presence in Chile, Ecuador, and Japan, and achieving 100% implementation of the BREEZE platform for streamlined health information exchange. The company has strengthened its partnership with the American Diabetes Association to advance chronic disease prevention and expanded its DaVita Health Tour providing free health screenings.

DaVita's commitment to sustainability is demonstrated through its progress toward 100% renewable energy usage globally, following its achievement of this goal in the U.S. in 2021. The company has received recognition from major publications including USA Today, Newsweek, and TIME as a leading employer and force for good.